Loading...
Loading...
Medtronic, Inc.
today announced the
first patient enrollments in the SubQStim II pivotal clinical trial to pursue
U.S. Food and Drug Administration (FDA) approval of peripheral nerve
stimulation (PNS), also known as subcutaneous nerve stimulation (SQS), for the
reduction of chronic, intractable post-surgical back pain.
PNS involves an implant of electrical leads just under the skin of the lower
back. These leads are connected to a stimulator which delivers mild electrical
impulses to the nerves, interrupting pain signals traveling through the
nervous system to the brain. Medtronic received CE (Conformité Européenne)
Mark for the first 16-electrode, fully implantable system for the percutaneous
delivery of PNS in the management of chronic back pain in May 2011. PNS using
a fully implantable system is not currently approved by the U.S. Food and Drug
Administration for use in the United States.
The SubQStim II pivotal study is a randomized, controlled, blinded, parallel
arm, multicenter trial to assess the safety and efficacy of PNS for chronic,
intractable post-surgical back pain. The study will recruit up to 323 people
at 30 U.S. centers who will receive PNS using a Medtronic neurostimulation
system. Subjects will be randomized to a treatment or control group for the
first three months and will continue to participate in open label follow-up
for up to five years.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in